Screening is defined as the presumptive identification of unrecognized disease or defect by the application of tests, examinations, or other procedures that can be applied rapidly and carned out in the general population or in indMduals at high risk. When onsidering immunochemical or biochemical cancer markers, it might be more appropriate to descnbe these tests as risk-factor monitors and introduce the concept of two interpretations of these tests: in asymptomatic populations as indicators of probability of cancer, and in patients with previously treated cancer as predictors of recurrence despite initial treatment descnbed as "curative. it has been suggested that screening is the testing of apparently healthy volunteers from the general population to separate them into those with high and low probability of having a disease (2). As new technology is developed, the definition must include the use of tests to assess risk factors for cancer and to predict individuals with "successfully" treated cancer who will have a recurrence.
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The past decade has seen great controversy over the cost and clinical effectiveness of screening to detect unrecognized cancer. In some cancers there is convincing data supporting the contention that early detection will decrease mortality.
Studies throughout the world have
shown that in women of ages >50 years, breast cancer detection programs can greatly reduce mortality.
In a large study in the US (62 000 women monitored for >20 years), the mortality in screened women (mainmography and clinical examination) was 50% lower at 5 years than in unscreened women (3). It is not yet established whether screening women younger than 50 years results in reduced mortality.
Assuming a cost of mammography of US$50 per patient, the total cost of screening all women in the US over age 50 would be US$2 000 000 000 per year (4). AFP were used, suggested that AFP was useful in screening in China but not in Africa and indicated biological differences in HCC. In Senegal, 9000 males were screened over 3 years; of the three cases of HCC detected, one was resectable.
In South Africa 9000 gold miners were screened and no cancers were detected (9,
14).
In China the screening program started 20 years ago and has been very intense.
Screening has been performed in 29 provinces and 2392 counties in a total population of >840 000 000 by 250000 physicians and 600 000 assistants. Of course, it is not known whether the cases discovered by screening would ever become lethal cancers.
Perhaps the most exciting prospects in colorectal cancer are the possibility of using genetic markers to isolate individuals at high risk for cancer at some later date, perhaps even 20 years later. The complex genetic deletions involved in the lengthy progression of normal colonic mucosa through the polyp stage to adenocarcinoma have been described, and fecal measurements of one of the oncogenes has been proposed as a possible marker for risk-factor assessment (23, 24). In a preliminary study, mutations of the ras oncogene were studied in feces from patients with curable colorectal cancer (24). The mutation looked for was K-ras in codons 12 or 13, which is known to occur in colon cancer tissue. Of 24 tissue specimens, 9 (37%) contained the mutation. The oncogene mutation was detected in DNA purified from stool in 6 of 7 patients with colon cancer who expressed the mutation in tissue. Three other patients who did not express the tissue mutation did not exhibit the oncogene in their stool, just as was the case for three healthy individuals. it will be possible to identify on the day of surgery the subset of women with negative lymph nodes and small tumors who will have an early recurrence of cancer.
Mutation in the ras

Prostate Cancer
Prostate cancer is the most common cancer of men in the US and has the second highest mortality rate (40). In 1992 it was estimated there would be 132 000 new cases and 34000 deaths. Between 1973 and 1989 the prostate cancer mortality rate increased by -16%. The incidence is age-related, and in men between 55 and 59 it is 94/100 000; in those over 65, the incidence is 740! 100 000; and in men over 85, 1146/100 000(41). Autopsy reports indicate an incidence of 38 000/100 000 in men between ages 50 and 70 (42) (43) . For men in high-risk groups or those with family histories of the disease, the Board recommended that PSA screening start at a younger age.
Despite this recommendation,
it is still controversial whether PSA can be useful in screening. The most extensive screening study included 1653 healthy men over 50 (44) . PSA values were measured in serum from these men on two occasions over a 6-month period. All those with values <4.0 jg/L at both measurements (1516 men or 92% of the population) were not studied further. There were 107 (6%) who had values between 4.1 and 9.9 g/L; of the 85 of these who had ultrasound-guided biopsies, 14 (22%) were positive. In the 30 (2%) men with values >10.0 gfL, 27 had biopsies and 18 (67%) were positive.
The control group was 235 men who had urinary symptoms and were attending a urology clinic. Seventyfour (32%) of these had PSA values between 4.1 and 9.9 ig/L, and 19 (26%) of these were biopsy-positive. In 45 men (14%) with values >10 g'L, 29 It must be considered an adjunct to but not a replacement for digital examination."
In another large study, 1002 men in Quebec City were included; the PSA cutoff was 3 g'L. At this value, the sensitivity was 89.6% and the predictive value of a negative result rate was 98.6%. Of the 57 cancers detected, 16 were in men with PSA between 3 and 4 .igfL (50).
A 20-year retrospective study of PSA in serum specimens collected from a geriatric population gives increased support to the usefulness of PSA in screening (51). In those men who never developed a malignancy, the PSA increased slightly in a linear fashion over time. The linear increase was somewhat greater in those with benign prostatic hypertrophy.
However, in men who
